Novavax adds blinded crossover arms to COVID-19 vaccine tria

Apr 6, 2021 7:45am
Novavax articulated its crossover plans alongside an update on the testing of its NVX-CoV2373 vaccine in children. (Novavax)
Novavax has added crossover arms to late-phase clinical trials of its COVID-19 vaccine. The action will enable participants in the placebo cohorts of the original trials to get vaccinated without unblinding the studies.
Participants in the 15,000-subject U.K. trial and 30,000-subject U.S.-Mexico study, which is yet to post data, will be offered the chance to get an additional round of injections. People who originally got a placebo will get two doses of the vaccine, and people who originally got the vaccine will receive two doses of placebo. 

Related Keywords

South Africa , South African , , Pfizer , International Coalition Of Medicines Regulatory Authorities , Johnson , International Coalition , Medicines Regulatory Authorities , Novavax , Corona Virus , Covid 19 , Vaccines , Clinical Trial Design , Biotech , ஃபைசர் , சர்வதேச கூட்டணி ஆஃப் மருந்துகள் ஒழுங்குமுறை அதிகாரிகள் , ஜான்சன் , சர்வதேச கூட்டணி , மருந்துகள் ஒழுங்குமுறை அதிகாரிகள் , கொரோனா வைரஸ் , தடுப்பு மருந்துகள் , மருத்துவ சோதனை வடிவமைப்பு , பயோடெக் ,